

## SECTOR UPDATE

## Banking – Singapore

The Interest Rate Cycle Has Reversed Course

**Based on the dot plot, the Fed Funds Rate is expected to ease 75bp in 2024 and 100bp in 2025. The interest rate downcycle is facilitated by a decline in inflation as supply-side distortions are normalised. The interest rate downcycle has negative impact on Singapore banks' NIM and net interest income. Downgrade to MARKET WEIGHT. Our top BUY is OCBC (Target: S\$16.85) for its new dividend policy with payout ratio at 50%, focus on ASEAN and defensively low P/B of 1.06x.**

## WHAT'S NEW

- The interest rate cycle has reversed course.** The Fed paused rate hike for the third consecutive FOMC meeting on 13 Dec 23. We expect the Fed to commence rate cuts in 2H24. Based on the dot plot, the median projected path for Fed Funds Rate is 4.6% by end-24 (previous: 5.1%) and 3.6% by end-25 (previous: 3.9%), indicating rate cuts of 75bp in 2024 and 100bp in 2025. The dovish bias can be seen from the downward shift in the dot plot by 50bp in 2004 and 30bp in 2025.
- Not if but when.** The FOMC has started to deliberate on the appropriate timing for rate cuts. Fed officials do not want to cause unintended harm to the economy by keeping interest rates too high for too long when inflation is falling. All three categories, namely manufactured goods, housing services and core services, are contributing to lower inflation. Chair Jerome Powell also confirmed that the Fed would not wait until PCE inflation returns to 2% before cutting interest rates.
- Inflation has turned the corner.** US core PCE inflation peaked at 5.6% in Feb 22, the fastest pace in 30 years. Core PCE inflation eased 1.9ppt yoy to 3.2% in Nov 23. Sequential momentum has also moderated to 0.1% mom. Based on economic projections provided by FOMC members as of Dec 23, the US economy is expected to expand by 1.4% and core PCE inflation to recede to 2.4% in 2024, which reflect continued economic expansion and a likely soft landing.
- COVID-19-induced supply-side distortions have normalised.** The Global Supply Chain Pressure Index devised by the Federal Reserve Bank of New York indicates that supply chains have fully normalised to pre-pandemic efficiency since 1Q23, which coincide with China's reopening after abandoning the zero-COVID policy. Overheated US labour market has started to cool. US labour force participation rate for those aged 25 to 54 has improved 1.0ppt ytd to 83.5% in Nov 23, moving above pre-pandemic levels. Thus, average hourly earnings eased slightly to 4.0% yoy in Nov 23 (peak: 6.3%).
- Asset quality - withstood test from COVID-19 pandemic.** The three Singapore banks have weathered the COVID-19 pandemic with NPL ratio deteriorating on average by just 0.1ppt. DBS' and OCBC's NPL ratios have slipped 0.2ppt to a similar 1.1% over the past three quarters. Banks have ample management overlays for general provisions amounting to about S\$2,200m for DBS, S\$1,000m for OCBC and S\$1,000m for UOB.
- Capital adequacy - among the safest in the world.** OCBC has the highest CET-1 CAR at 15.9% as of Mar 23, followed by DBS at 14.4%, far exceeding the minimum requirement of 9%. DBS is ranked 12th safest on a worldwide basis by Global Finance, followed by OCBC at 13th. Within Asia, the three Singapore banks are recognised as the top 3 safest ahead of banks in South Korea, Taiwan and Hong Kong.

## PEER COMPARISON

Company	Ticker	Rec	Price @	Target	Market	FY	PE		P/B		P/POP		Yield		ROE	
			29 Dec 23	Price (\$\$)	Cap (US\$m)		2024F	2025F	2024F	2025F	(x)	(x)	(%)	(%)	(%)	(%)
DBS	DBS SP	BUY	33.41	41.65	65,275	12/2022	8.6	9.1	1.35	1.26	7.2	7.6	5.7	5.7	15.6	13.8
OCBC	OCBC SP	BUY	13.00	16.85	44,258	12/2022	8.4	8.8	1.06	1.00	7.3	7.6	6.2	6.2	12.7	11.5
UOB#	UOB SP	NR	28.45	n.a.	36,043	12/2022	8.1	7.9	1.01	0.95	6.0	5.8	6.3	6.4	12.9	12.5
<b>Average</b>							<b>8.4</b>	<b>8.6</b>	<b>1.14</b>	<b>1.07</b>	<b>6.8</b>	<b>7.0</b>	<b>6.1</b>	<b>6.1</b>	<b>13.7</b>	<b>12.6</b>

#Based on consensus estimate      Source: Bloomberg, UOB Kay Hian

## MARKET WEIGHT


(Downgraded)

## TOP BUYS


Company	Rec	Share Price (\$\$)	Target Price (\$\$)
DBS	BUY	33.41	41.65
OCBC	BUY	13.00	16.85

Source: UOB Kay Hian


## P/B - DBS



## P/B - OCBC



## P/B - UOB



## ANALYST(S)

Jonathan Koh, CFA, MSc Econ

+65 6590 6620

jonathan.koh@uobkayhian.com

### ACTION

- Downgrade to MARKET WEIGHT.** The anticipated interest rate down-cycle has a negative impact on Singapore banks. Rate cuts are expected to result in NIM compression and lower net interest income in 2H24 and 2025. Valuations are undemanding with Singapore banks trading at low P/B of 1.14x, low PE of 8.4x and attractive dividend yield of 6.1% for 2024.

#### Oversea-Chinese Banking Corp (BUY/Target: S\$16.85).

- Our top pick is OCBC due to its commitment to maintain dividend payout ratio at 50%, consistency in delivering growth in quarterly earnings, focus on trade and investment flows within ASEAN and defensively low 2024F P/B of 1.06x. It has the highest CET-1 CAR of 14.8% and lowest NPL ratio of 1.0% as of Sep 23.

#### DBS Group Holdings (BUY/Target: S\$41.65).

- We also like DBS for its excellence in execution and consistently delivering good results. Management estimated surplus capital at S\$3b or S\$1.20 per share based on optimal operating range for CET-1 CAR of 12.5-13.5%. DBS could consider potential capital management exercise to return surplus capital to shareholders over three years given that Final Basel III Reforms are already finalised and would be implemented starting 1 Jul 24.

### PROJECTED DPS AND DIVIDEND PAYOUT RATIOS

	DBS			OCBC			UOB#		
Price (S\$)	33.41			13.00			28.45		
Year to 31 Dec	FY23	FY24F	FY25F	FY23	FY24F	FY25F	FY23	FY24F	FY25F
EPS (S ¢)	397	387	366	155	154	148	342	352	361
DPS (S ¢)	186	192	192	80	80	80	172	179	181
Payout Ratio (%)	46.9	49.7	52.4	51.7	51.9	54.1	50.4	50.9	50.1
Dividend Yield (%)	5.6	5.7	5.7	6.2	6.2	6.2	6.1	6.3	6.4

# Based on consensus estimate

Source: UOB Kay Hian

### ASSUMPTION CHANGES

- We forecast DBS' NIM to narrow 8bp in 2024 and 25bp in 2025. We expect net interest income to increase 1.8% in 2024 but decline 8.0% in 2025. We forecast earnings decline of 5.2% in 2025. The interest rate down-cycle reduces 2025 ROE by 3.7ppt to 14.2% compared with its recent peak (2023: 17.9%).


### KEY ASSUMPTIONS - DBS

	2021	2022	2023F	2024F	2025F
Loan Growth (%)	9.9	1.3	2.4	4.9	4.9
NIM (%)	1.45	1.75	2.16	2.08	1.83
Fees, % Chg	15.2	(12.3)	11.4	16.2	7.7
NPL Ratio (%)	1.27	1.13	1.18	1.24	1.26
Credit Costs (bp)	0.6	5.4	14.6	20.1	20.1
Net Profit (\$m)	6,802	8,196	10,124	9,942	9,421
% Chg	44.1	20.5	23.5	(1.8)	(5.2)


Source: UOB Kay Hian

- We forecast OCBC's to NIM narrow 8bp in 2024 and 22bp in 2025. We expect net interest income to increase 0.5% in 2024 but decline 5.9% in 2025. We forecast earnings decline of 4.1% in 2025. The interest rate down-cycle reduces 2025 ROE by 1.7ppt to 11.7% compared with its recent peak (2023: 13.5%).


### US FED FUNDS RATE VS 3M SIBOR AND 3M SORA




### FED'S DOT PLOT (DEC 23 VS SEP 23)



### NET INTEREST MARGIN (NIM)



### CREDIT COSTS



## KEY ASSUMPTIONS – OCBC

	2021	2022	2023F	2024F	2025F
Loan Growth (%)	8.6	1.8	1.5	3.4	4.9
NIM (%)	1.55	1.91	2.27	2.19	1.97
Fees, % Chg	12.0	(17.6)	(0.5)	13.7	7.6
NPL Ratio (%)	1.45	1.15	1.03	1.07	1.09
Credit Costs (bp)	31.3	20.0	23.9	22.3	23.3
Net Profit (S\$m)	4,858	5,748	7,020	6,998	6,712
% Chg	35.4	18.3	22.1	(0.3)	(4.1)

Source: UOB Kay Hian

## SECTOR CATALYSTS

- Soft landing paving the way for continued economic growth.
- Banks reviewing their dividend policy and capital management.

## RISKS

- Escalation of the Russia-Ukraine war and Israel-Hamas war.
- Geopolitical tension and trade conflict between the US, EU and China.

### Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

**This report is prepared for general circulation.** It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

### IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

**Analyst Certification/Regulation AC**

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2024, UOB Kay Hian Pte Ltd. All rights reserved.

<http://research.uobkayhian.com>

RCB Regn. No. 197000447W